Third-party regulatory T cells prevent murine acute graft-versus-host disease
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Adoptive therapy with regulatory T (Treg) cells to prevent graftversus- host disease (GVHD) would benefit from a strategy to improve homing to the sites of inf lammation following hematopoietic stem cell transplantation (HSCT). Although donor-derived Treg cells have mainly been used in these models, third-party-derived Treg cells are a promising alternative for cell-based immunotherapy, as they can be screened for pathogens and cell activity, and banked for GVHD prevention. In this study, we explored major histocompatibility complex (MHC) disparities between Treg cells and conventional T cells in HSCT to evaluate the impact of these different cell populations on the prevention of acute GVHD, as well as survival after allogeneic transplantation. Methods: To induce acute GVHD, lethally irradiated BALB/c (H-2d) mice were transplanted with 5 × 105 T cell-depleted bone marrow cells and 5 × 105 CD4+CD25– splenic T cells from C57BL/6 (H-2b) mice. Recipients were injected with 5 × 105 cultured donor-, host-, or third-party-derived CD4+CD25+CD62L+ Treg cells (bone marrow transplantation + day 1). Results: Systemic infusion of three groups of Treg cell improved clinicopathological manifestations and survival in an acute GVHD model. Although donor-derived Treg cells were immunologically the most effective, the third-party-derived Treg cell therapy group displayed equal regulation of expansion of CD4+CD25+Foxp3+ Treg cells and suppressive CD4+IL-17+ T-helper (Th17) cells in ex vivo assays compared with the donor- and host-derived groups. Conclusions: Our findings demonstrate that the use of third-party Treg cells is a viable alternative to donor-derived Treg cellular therapy in clinical settings, in which human leukocyte antigen-matched donors are not always readily available.
Abstract
Background/Aims: Adoptive therapy with regulatory T (Treg) cells to prevent graftversus- host disease (GVHD) would benefit from a strategy to improve homing to the sites of inf lammation following hematopoietic stem cell transplantation (HSCT). Although donor-derived Treg cells have mainly been used in these models, third-party-derived Treg cells are a promising alternative for cell-based immunotherapy, as they can be screened for pathogens and cell activity, and banked for GVHD prevention. In this study, we explored major histocompatibility complex (MHC) disparities between Treg cells and conventional T cells in HSCT to evaluate the impact of these different cell populations on the prevention of acute GVHD, as well as survival after allogeneic transplantation. Methods: To induce acute GVHD, lethally irradiated BALB/c (H-2d) mice were transplanted with 5 × 105 T cell-depleted bone marrow cells and 5 × 105 CD4+CD25– splenic T cells from C57BL/6 (H-2b) mice. Recipients were injected with 5 × 105 cultured donor-, host-, or third-party-derived CD4+CD25+CD62L+ Treg cells (bone marrow transplantation + day 1). Results: Systemic infusion of three groups of Treg cell improved clinicopathological manifestations and survival in an acute GVHD model. Although donor-derived Treg cells were immunologically the most effective, the third-party-derived Treg cell therapy group displayed equal regulation of expansion of CD4+CD25+Foxp3+ Treg cells and suppressive CD4+IL-17+ T-helper (Th17) cells in ex vivo assays compared with the donor- and host-derived groups. Conclusions: Our findings demonstrate that the use of third-party Treg cells is a viable alternative to donor-derived Treg cellular therapy in clinical settings, in which human leukocyte antigen-matched donors are not always readily available.
참고문헌 (22)
- Cao J, "Influence of donor Treg cells on GVHD and GVL effects after allogeneic bone marrow transplantation in mice", Zhongguo Shi Yan Xue Ye Xue Za Zhi, 18, pp.181~184 (2010)
- Kataoka Y, "The role of donor T cells for target organ injuries in acute and chronic graftversus-host disease", Immunology, 103, pp.310~318 (2001)[DOI]
- Gallatin WM, "A cell-surface molecule involved in organ-specific homing of lymphocytes", Nature, 304, pp.30~34 (1983)[DOI]
- Fu S, "CD4+ CD25+ CD62+ T-regulatory cell subset has optimal suppressive and proliferative potential", Am J Transplant, 4, pp.65~78 (2004)[DOI]
- Brunstein CG, "Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics", Blood, 117, pp.1061~1070 (2011)[DOI]
- Jeon EJ, "Adoptive transfer of all-trans-retinal-induced regulatory T cells ameliorates experimental autoimmune arthritis in an interferon-gamma knockout model", Autoimmunity, 45, pp.460~469 (2012)[DOI]
- Fukui J, "Prevention of graft-versushost disease by intra-bone marrow injection of donor T cells", Stem Cells, 25, pp.1595~1601 (2007)[DOI]
- Lee ES, "adoptive transfer of treg cells combined with mesenchymal stem cells facilitates repopulation of endogenous Treg cells in a murine acute GVHD model", PLoS One, 10, pp.e0138846~ (2015)[DOI]
- Lim JY, "Combination cell therapy using mesenchymal stem cells and regulatory T-cells provides a synergistic immunomodulatory effect associated with reciprocal regulation of TH1", TH2 and th17, Cell Transplant, pp.2014, 23[DOI]
- Shi M, "Combination of intra-bone marrow-bone marrow transplantation and subcutaneous donor splenocyte injection diminishes risk of graft-versus-host disease and enhances survival rate", Stem Cells Dev, 20, pp.759~768 (2011)[DOI]
- Riley JL, "Human T regulatory cell therapy: take a billion or so and call me in the morning", Immunity, 30, pp.656~665 (2009)[DOI]
- Fozza C, "Regulatory T cells in stem cell transplantation: main characters or walk-on actors?", Crit Rev Oncol Hematol, 84, pp.18~25 (2012)[DOI]
- Rezvani K, "High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT", Blood, 108, pp.1291~1297 (2006)[DOI]
- Li Q, "Decrease of CD4(+)CD25(+) regulatory T cells and TGF-beta at early immune reconstitution is associated to the onset and severity of graft-versushost disease following allogeneic haematogenesis stem cell transplantation", Leuk Res, 34, pp.1158~1168 (2010)[DOI]
- Koenecke C, "Alloantigen-specific de novo-induced Foxp3+ Treg revert in vivo and do not protect from experimental GVHD", Eur J Immunol, 39, pp.3091~3096 (2009)[DOI]
- Beres AJ, "CD8+ Foxp3+ regulatory T cells are induced during graft-versus-host disease and mitigate disease severity", J Immunol, 189, pp.464~474 (2012)[DOI]
- Zheng SG, "CD4+ and CD8+ regulatory T cells generated ex vivo with IL-2 and TGF-beta suppress a stimulatory graft-versus-host disease with a lupus-like syndrome", J Immunol, 172, pp.1531~1539 (2004)[DOI]
- Yamashita J, "Effect of zoledronate on oral wound healing in rats", Clin Cancer Res, 17, pp.1405~1414 (2011)[DOI]
- Lu SY, "High frequencies of CD62L+ naive regulatory T cells in allografts are associated with a low risk of acute graft-versus-host disease following unmanipulated allogeneic haematopoietic stem cell transplantation", Clin Exp Immunol, 165, pp.264~277 (2011)[DOI]
- Taylor PA, "L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection", Blood, 104, pp.3804~3812 (2004)[DOI]
- Ermann J, "Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD", Blood, 105, pp.2220~2226 (2005)[DOI]
- Parmar S, "Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease", Cytotherapy, 16, pp.90~100 (2014)[DOI]